Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57634

Kempf, W; Pfaltz, K; Vermeer, M H; Cozzio, A; Ortiz-Romero, P L; Bagot, M; Olsen, E; Kim, Y H; Dummer, R; Pimpinelli, N; Whittaker, S; Hodak, E; Cerroni, L; Berti, E; Horwitz, S; Prince, H M; Guitart, J; Estrach, T; Sanches, J A; Duvic, M; Ranki, A; Dreno, B; Ostheeren-Michaelis, S; Knobler, R; Wood, G; Willemze, R (2011). EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood, 118(15):218-225.

[img]
Preview
Published Version
PDF
630kB

Abstract

Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:12 Feb 2012 11:00
Last Modified:29 Nov 2013 12:38
Publisher:American Society of Hematology
ISSN:0006-4971 (P) 1528-0020 (E)
Additional Information:This research was originally published in Blood. Blood. 2011 Oct 13;118(15):4024-35. Copyright by the American Society of Hematology.
Publisher DOI:10.1182/blood-2011-05-351346
PubMed ID:21841159
Citations:Web of Science®. Times Cited: 37
Google Scholar™
Scopus®. Citation Count: 47

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page